Infertility Drugs Market

Infertility Drugs Market Size:

The global infertility drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032. Increasing infertility rates, advancements in assisted reproductive technologies (ART), supportive government initiatives, rising healthcare expenditure, new pharmaceutical developments, availability of insurance coverage, and the proliferation of fertility clinics are some of the factors accelerating the market growth.

Infertility Drugs Market Analysis:

• Major Market Drivers: Increase in awareness about infertility and reproductive health, especially in emerging economies, is driving the need for fertility treatment, making it one of the most significant factors fueling the market growth. Additionally, accessibility of advanced drug delivery systems has elevated the market growth by scaling up effectiveness of new fertility drugs. Furthermore, escalating stress levels and increasing government undertakings to support fertility treatments are boosting the infertility drugs market revenue. In addition to this, the growing requirement for non-invasive treatment has initiated several drug development pipelines, which is propelling market growth.
• Key Market Trends: The growing consumer preference for personalized medicine, is boosting the market growth. Moreover, the rapid expansion in telemedicine and online consultations has increased the availability of fertility treatment, especially in remote areas, which is further offering lucrative opportunities for the market expansion. In addition to this, surging prevalence of male infertility with the rising adoption for natural and hormone-free treatment are providing a positive infertility drugs market outlook. Furthermore, the leading pharmaceutical companies are actively working towards reducing the side effect of the drugs and improving patient compliance, which is accelerating market growth.
• Geographical Trends: North America holds the largest infertility drugs market share due to the presence of robust healthcare facilities and substantial investment in research & development (R&D). The US holds a major share in the regional market as the country is backed with the rising cases of infertility and availability of advanced technologies in fertility clinics. As per the infertility drugs market forecast, Europe holds a significant share on account of the favorable government policies and the growing use of fertility treatments. On the other hand, in Asia-Pacific, the market is driven by the surging awareness regarding infertility treatment, establishment of advanced healthcare facilities, and burgeoning per capita income.
• Competitive Landscape: Some of the major market players in the infertility drugs industry include Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex, among many others.
• Challenges and Opportunities: As per the infertility drugs market overview, one of the primary challenges include the relatively high treatment costs, especially in developing regions. Furthermore, social stigmas related to infertility and its treatment is another factor restraining the market growth. However, the growing acceptance of fertility treatments and rising awareness about infertility problems are key opportunities for the infertility drugs market. Additionally, the development in technology and the innovation of new drugs with reduced side effects are driving the market growth.

Infertility Drugs Market Trends:

Increasing Prevalence of Infertility

Globally, rapid lifestyle changes and delayed pregnancies have led to rise in infertility rates , which is accelerating the market growth. As per the industry report, in India, around 18.7/1000 women of all reproductive age group, being in a relationship for five years, experienced infertility. This can be attributed to the heightened stress, poor diet, and sedentary lifestyles. Furthermore, the proliferation of infertility cases has substantially surged the demand for various medical treatment approaches, which, is fueling the market growth. In addition to this, the increasing accessibility of fertility treatments and growing per capita income are contributing to the market growth.

Growing Awareness and Government Initiatives

Increasing understanding of infertility problems and favorable government programs are key factors facilitating the market growth. Moreover, the establishment of numerous health campaigns and educational programs conducted by both governments and non-governmental organizations are stimulating the market growth. These efforts are focused on eradicating societal stigmas regarding infertility, which has further surged the patients willingness to seek medical assistance, further fueling the market growth. Additionally, the governments are also launching policies and programs for people seeking infertility treatments, such as subsidies, tax benefits, and expanding insurance coverage, which is driving the market growth.

Advancements in Assisted Reproductive Technologies (ART)

Rapid technological advancements, such as development of assisted reproductive technologies (ART), is the key factor supporting the market growth. The procedure involves various medical interventions that assists in conceiving naturally, such as in-vitro fertilization (IVF). Additionally, the enhancements in technologies have resulted to enormous parity success rates, which has further surged their demand among the consumers. Apart from this, the development of effective ovarian stimulation and genetic screening techniques are creating a positive outlook for the market.

Infertility Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug class, route of administration, distribution channel, and end user.

Breakup by Drug Class:

• Gonadotropin
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Biguanides
• Others
   

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes gonadotropin, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and others.

The gonadotropin segment is driven by the increasing use of these hormones in assisted reproductive technologies (ART), such as in vitro fertilization (IVF), where they play a crucial role in stimulating ovulation. The segment is also benefitting from ongoing advancements in gonadotropin formulations, which enhance efficacy and reduce side effects, making them a preferred choice among fertility specialists.

The aromatase inhibitors segment is driven by the growing recognition of these drugs as effective alternatives to traditional fertility treatments, particularly for women with polycystic ovary syndrome (PCOS). Their ability to induce ovulation with fewer side effects than other treatments is increasing their adoption in clinical practice, further driving this segment.

The selective estrogen receptor modulators (SERMs) segment is driven by the widespread use of these drugs, particularly Clomiphene Citrate, as a first-line treatment for infertility. Their affordability, effectiveness in inducing ovulation, and long-standing clinical track record make SERMs a key component in fertility treatments, particularly in regions with limited access to advanced ART.

The biguanides segment is driven by the increasing incidence of insulin resistance and metabolic disorders like PCOS, which are closely linked to infertility. Biguanides, particularly metformin, are used to improve insulin sensitivity, which can help restore normal ovulation in women with PCOS, thus driving demand in this segment.

The others segment is driven by the inclusion of various supportive and adjunctive therapies that are increasingly being recognized as important in comprehensive infertility treatment plans. This includes drugs that enhance endometrial receptivity, improve sperm quality, and support hormonal balance, expanding the scope of infertility treatment beyond traditional hormone therapies.

Breakup by Route of Administration:

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
   

A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes oral, intravenous, subcutaneous, and intramuscular.

The oral segment is driven by the increasing preference for ease of administration and convenience among patients. Oral infertility drugs are non-invasive and can be self-administered, which appeals to individuals who prefer to avoid frequent clinic visits. Additionally, the affordability of oral medications compared to other forms is a key factor, making them more accessible. The availability of various oral fertility drugs, such as clomiphene citrate, further boosts this segment, offering effective solutions for ovulation induction.

The intravenous segment is driven by the need for rapid and direct drug delivery, particularly in cases requiring immediate or controlled administration of fertility hormones. This method ensures a higher bioavailability of the drug, making it highly effective in specific treatments like in vitro fertilization (IVF) protocols. The use of intravenous administration is also favored in controlled ovarian hyperstimulation (COH), where precise dosing is critical for successful outcomes. The segment’s growth is supported by advancements in medical technologies and the increasing adoption of ART procedures.

The subcutaneous segment is driven by its balance of convenience and efficacy, allowing patients to administer fertility drugs at home with minimal discomfort. This method is commonly used for gonadotropins, which require consistent and precise administration. Subcutaneous injections are less invasive than intravenous methods and offer quicker absorption than oral drugs. The growing demand for user-friendly fertility treatment options and the availability of pre-filled injection pens and other easy-to-use delivery systems are contributing to the popularity and expansion of this segment.

The intramuscular segment is driven by its effectiveness in delivering drugs that require deep tissue absorption, making it ideal for specific hormone therapies in infertility treatment. Intramuscular injections are often used when larger volumes of medication are necessary or when a slower, sustained release of the drug is required. This method is favored in certain protocols for ART, where precise and controlled hormone levels are crucial. The segment is also supported by its established use in fertility treatments, trusted by healthcare professionals for delivering consistent therapeutic outcomes.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others
   

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and others.

The hospital pharmacies segment is driven by the increasing preference for hospital-based fertility treatments, where patients can access specialized care and immediate medical assistance. Hospitals are often equipped with advanced reproductive technologies and expert medical professionals, making them a trusted source for infertility medications. The segment also benefits from the direct availability of comprehensive healthcare services, including diagnostics, counseling, and treatment, all under one roof, ensuring continuity of care and patient convenience.

The retail pharmacies segment is driven by the growing accessibility and convenience of obtaining infertility drugs through local pharmacies. Retail pharmacies are increasingly stocking a wide range of fertility medications, making it easier for patients to access their prescriptions. Additionally, the rise of over-the-counter options for certain infertility treatments and the expansion of retail pharmacy chains into suburban and rural areas are further boosting this segment. The availability of online pharmacy services also contributes to the growth of this segment, offering patients a convenient and discreet way to purchase infertility medications.

The others segment is driven by the growing demand for infertility treatments in non-traditional settings such as online pharmacies, fertility clinics, and specialty drug stores. This segment is expanding due to the rise of telemedicine and direct-to-consumer sales, where patients can obtain infertility medications without visiting a hospital or retail pharmacy.

Breakup by End User:

• Male
• Female
   

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes male and female.

The female segment is driven by the increasing prevalence of conditions such as polycystic ovary syndrome (PCOS), endometriosis, and hormonal imbalances, which are significant contributors to female infertility. These conditions often require medical intervention through fertility drugs to regulate ovulation and improve reproductive outcomes. Additionally, advancements in assisted reproductive technologies (ART) like in vitro fertilization (IVF) have increased the demand for drugs that support egg maturation and implantation. The rising awareness of fertility issues, along with supportive government initiatives and healthcare campaigns, is encouraging more women to seek treatment.

The male segment is driven by the rising incidence of male infertility, which can be attributed to factors such as declining sperm count, poor sperm motility, and lifestyle-related issues like stress, smoking, and obesity. Medical advancements have led to the development of drugs that improve sperm quality, increase sperm count, and address hormonal imbalances that can affect male fertility. Growing awareness of male infertility and its impact on couples' ability to conceive is encouraging more men to seek treatment, leading to an increased demand for fertility drugs. Additionally, the integration of fertility treatments with assisted reproductive technologies (ART) for male factor infertility is further expanding this segment.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The infertility drugs market in North America is driven by advanced healthcare infrastructure, high awareness levels regarding infertility treatments, and a significant number of fertility clinics across the region. Additionally, rising infertility rates due to lifestyle factors, such as delayed childbearing and stress, are contributing to market growth. Continuous research and development (R&D) by pharmaceutical companies in the region are also leading to the introduction of innovative infertility drugs, which are widely adopted by healthcare providers and patients alike, which is further driving the infertility drugs market growth in the region.

In Asia Pacific, the infertility drugs market is growing rapidly due to increasing awareness of reproductive health issues and the availability of advanced infertility treatments. Economic growth in countries such as China, India, and Japan is leading to higher healthcare expenditure and improved access to fertility treatments, which is further accelerating the infertility drugs demand. Cultural shifts and urbanization are also contributing to lifestyle changes that increase the incidence of infertility. Government initiatives promoting fertility care, coupled with the expansion of healthcare facilities and the rising prevalence of infertility, are further fueling demand for infertility drugs across the region.

The infertility drugs market in Europe is primarily driven by a strong healthcare system, high awareness of infertility issues, and widespread access to advanced reproductive technologies. Countries such as Germany, France, and the United Kingdom have well-established fertility clinics that offer a range of treatment options, supported by government-funded healthcare programs. Additionally, the region’s aging population and delayed childbearing trends are leading to increased demand for infertility treatments.

Latin America’s infertility drugs market is expanding due to growing awareness of reproductive health and the increasing availability of infertility treatments in countries such as Brazil, Mexico, and Argentina. Economic improvements in the region are enabling greater healthcare investment, which in turn is improving access to fertility clinics and treatments.

In the Middle East and Africa, the infertility drugs market is growing as awareness of infertility treatments increases, particularly in urban areas. The rising prevalence of infertility due to lifestyle factors, combined with cultural importance placed on having children, is driving demand for effective treatment options. Economic development in countries like the UAE and South Africa is leading to improved healthcare infrastructure and access to fertility clinics.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the infertility drugs industry include Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Theramex, etc.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• Key infertility drugs companies in the market are focusing on strategic initiatives to strengthen their market presence and expand their product portfolios. They are heavily investing in research and development (R&D) to innovate new and more effective infertility drugs, including advanced hormonal therapies and ovulation stimulants. These companies are also forming strategic partnerships and collaborations with fertility clinics and healthcare institutions to enhance the distribution and accessibility of their products. Additionally, they are expanding their operations into emerging markets, where the demand for infertility treatments is growing due to increasing awareness and improving healthcare infrastructure. As per the infertility drugs market recent developments, key players are also emphasizing personalized medicine approaches, offering tailored treatments based on individual patient profiles.

Infertility Drugs Market News:

• In 2024, Ferring Pharmaceuticals entered into a strategic partnership with Posterity Health to enhance awareness and address male fertility issues. This collaboration aims to encourage men to take a proactive role in their reproductive health. The partnership leverages Posterity Health's expertise in male fertility with Ferring’s commitment to reproductive medicine, focusing on providing comprehensive care for couples facing infertility challenges.
• In 2021, Merck KGaA continues to strengthen its presence in the infertility drugs market with the recent launch of the Pergoveris Pen in India. This innovative product is designed to assist women undergoing assisted reproductive treatments by combining recombinant follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in a single, ready-to-use device.

Infertility Drugs Market Report Scope:

Key Questions Answered in This Report:

• How has the global infertility drugs market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global infertility drugs market?
• What is the impact of each driver, restraint, and opportunity on the global infertility drugs market?
• What are the key regional markets?
• Which countries represent the most attractive infertility drugs market?
• What is the breakup of the market based on the drug class?
• Which is the most attractive drug class in the infertility drugs market?
• What is the breakup of the market based on the route of administration?
• Which is the most attractive route of administration in the infertility drugs market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the infertility drugs market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the infertility drugs market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global infertility drugs market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the infertility drugs market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global infertility drugs market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the infertility drugs industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.